Jefferies reiterates Simply Goods stock rating on protein exposure By Investing.com

Jefferies reiterated a Buy on The Simply Good Foods (SMPL) with a $22 price target, implying ~44% upside from the $15.24 price; the stock is down 56% over the past year. The company reported 6.3% revenue growth LTM and a strong free cash flow yield of 12%, but faces near-term execution and inflation pressures. TD Cowen cut its PT to $20 from $24 (Hold) citing weakening retail sales in January, while Bernstein/SocGen kept an Outperform and $31 PT citing unchanged FY2026 guidance. Management changes (new VP IR & Treasury, new director) and shareholder approval of a new incentive plan were also announced.

Analysis

The market is treating the name as an execution story with a governance/valuation mismatch rather than a category-structural opportunity; that creates a two-way bet where operational momentum is the most likely near-term mover while strategic outcomes (activism, sale, buybacks) drive medium-term rerating. Expect channel dynamics — retailer inventory digestion and club/online mix shifts — to create lumpy revenue prints for the next 2–3 quarters; a steady sequential gross‑margin recovery thereafter would be the clearest proof that pricing and cost levers are working.

Second‑order winners include co‑packers and ingredient suppliers that can flex capacity quickly to meet branded reformulation or private‑label demand, while multi‑category CPG incumbents that can cross‑promote protein positioned SKUs will take share if shelf resets favor convenience/protein. Conversely, smaller single‑format independents without scale in procurement will see margin pressure first as input cost passthrough lags. Management moves on IR and the board increase the probability of near‑term capital‑markets activity (targeted buybacks, incentive re‑pricing, or a strategic review) — treat those as discrete binary catalysts over the next 6–12 months.

Tail risks are classic: protracted retail demand weakness, deflationary price resets, or a competitor price war that forces margin sacrifice; each would materially compress free cash flow and delay any revaluation. The clean reversals are equally identifiable — sustained sequential gross‑margin expansion, consistent retail sell‑through across major channels, or visible capital returns — and would likely compress downside rapidly. From a timing lens, trade the equity as a tactical recovery with a 6–18 month horizon but monitor daily retail sell‑through and weekly co‑packer utilization as high‑signal metrics for position sizing adjustments.

Key Decisions for Investors

• Establish a core long position in SMPL (size 2–4% NAV) with a 6–18 month horizon; add on two sequential quarters of margin improvement. Risk: set a hard stop at ~20% drawdown from entry if sell‑through and gross‑margin do not show sequential improvement within 3 quarters. Reward: asymmetric upside from rerating or strategic bid — target a minimum 2.5–3x upside/downside ratio over the holding period.
• Buy-write for income: buy SMPL equity and sell 3–6 month out‑of‑the‑money calls (one to two strikes OTM) to harvest premium while waiting for operational fixes. Rationale: lowers breakeven and monetizes near‑term volatility; downside remains equity risk so keep covered allocation <3% NAV and roll if volatility compresses.
• Pair trade for idiosyncratic recovery: long SMPL (1.5–3% NAV) / short XLP (or a large-cap staples ETF) size-matched to remove broad staples beta, 6–12 month horizon. Rationale: isolates company‑specific operational recovery vs sector; unwind if sector diverges >5% intraperiod or if SMPL underperforms its peers for two consecutive quarters.
• Cost‑efficient downside protection: buy 9–12 month put spreads on SMPL sized to cover 50–70% of the position not hedged by options income. Structure as a 1:2 long put:short put spread to limit premium while protecting tail risk — expected cost ~low single‑digit % of NAV for the protected tranche, delivering controlled downside with capped cost.